Intensity Therapeutics, Inc. INTS 深 沪
等待开盘 10-09 09:30:00 美东时间
3.68
-0.120
-3.16%
华盛通- 最 高3.80
- 今 开3.76
- 成交量 1.92万股
- 最 低 3.58
- 昨 收 3.80
- 总市值 1201.48万
- 52周最高 43.50
- 市盈率 静 --
- 换手率 0.59%
- 52周最低 3.21
- 委 比 -68.63%
- 总股本 326.49万
- 历史最高 286.00
- 量 比 1.14
- 振 幅 5.79%
- 历史最低 3.58
- 每 手 1
- 风险率 3.30%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅167.3%！HC Wainwright上调Tango Therapeutics目标价至68美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Tango Therapeutics"买入"评级，目标价从66美元升至68美元；康托·菲茨杰拉德：维持Duos Technologies Group"超配"评级，目标价从26美元升至27美元
08-19 08:37
HC Wainwright & Co. Maintains Buy on Intensity Therapeutics, Raises Price Target to $7
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Intensity Therapeutics (NASDAQ:INTS) with a Buy and raises the price target from $5 to $7.
08-19 01:40
Intensity Therapeutics Q2 EPS $(1.11), Inline
Intensity Therapeutics (NASDAQ:INTS) reported quarterly losses of $(1.11) per share which met the analyst consensus estimate. This is a 66.96 percent increase over losses of $(3.36) per share from the same period last year.
08-11 19:52
Intensity重启三阴性乳腺癌术前II期临床试验患者入组
生物技术公司Intensity Therapeutics宣布，已恢复其INVINCIBLE-4研究的患者治疗与入组工作。该研究是一项针对早期可手术三阴性乳腺...
07-15 22:09
Intensity Therapeutics Administers New Patients With INT230‑6 In INVINCIBLE‑4 Switzerland Study; Trial Evaluates pCR Rates Vs Null Hypothesis Across SOC And INT230‑6+SOC Cohorts
First patients dosed in Switzerland SHELTON, Conn., July 15, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (NASDAQ:INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed t...
07-15 19:48
Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award
Company receives the Cancer Treatment Technology Innovator of the Year award SHELTON, Conn., May 14, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc., (Nasdaq: INTS) ("Intensity" or the "Co...
05-14 20:00
Intensity Therapeutics Q1 EPS $(0.96) Beats $(1.11) Estimate
Intensity Therapeutics (NASDAQ:INTS) reported quarterly losses of $(0.96) per share which beat the analyst consensus estimate of $(1.11) by 13.51 percent. This is a 82.55 percent increase over losses of $(5.50) per share
05-08 04:50
Intensity Therapeutics Q1 EPS $(0.96) Beats $(1.11) Estimate
Unity Software(U.US) reported fourth-quarter financial results after the market...
05-08 04:50
快讯 | Intensity Therapeutics 第一季度营业总收入（单位：美元）-252.6万
Intensity Therapeutics Q1 Operating Income USD -2.526 Million
05-08 04:06
